Abstract:Purpose: A novel 18F-radiolabeled somatostatin analogue, [Al18F]NODA-MPAA-HTA, was synthesized and evaluated for positron emission tomography (PET) imaging of Neuroendocrine tumors (NETs). [Al18F]NODA-MPAA-HTA was designed and synthesized by conjugating 18F nuclide with a modified KE108 peptide, a somatostatin analog with high affinity for all five subtypes of somatostatin receptors (SSTR 1-5), through coupling a bifunctional chelator (NODA) to target somatostatin receptor (SSTR) positive tumors. Methods: The amino group of KE108 peptide, a SSTRs-targeting pharmacophore, was conjugated with the carboxyl group of NODA by a condensation reaction to obtain the labeling precursor of [Al18F]NODA-MPAA-HTA, in which its precursor was obtained through Fmoc solid-phase methods. A novel methodology for Al18F labeling of chelating agent-biomolecule conjugates was used to synthesize [Al18F]NODA-MPAA-HTA. In vitro stabilities of [Al18F]NODA-MPAA-HTA were evaluated by incubating it in saline or bovine serum for 2 h. Ex vivo biodistribution and in vivo imaging of [Al18F]NODA-MPAA-HTA were further investigated to evaluate its SSTRs targeting ability and feasibility for the diagnosis of NETs using PET imaging. Results: [Al18F]NODA-MPAA-HTA was synthesized using a one-step 18F-AlF labeling procedure resulting in moderate radiochemical yield (60-80 %, non-decay corrected) and high radiochemical purity (>95 %). It exhibited good hydrophilicity and excellent stability in vitro, with a molar activity of 122 GBq/μmol. At 30 min and 60 min, the uptake of [Al18F] NODA-MPAA-HTA by HEK293-SSTR2 cells was 5.47 ± 0.97 %/105 cells and 12.11 ± 0.32 %/105 cells, respectively. The affinity of [Al18F]NODA-MPAA-HTA for SSTR2 was determined to be 8.77 ± 1.14 nM. In micro-PET imaging of HEK293-SSTR2 tumor-bearing mice, [Al18F]NODA-MPAA-HTA showed high tumor uptake of radioactivity and a high tumor-to-muscle ratio. Biodistribution results confirmed that radioactivity uptake in the tumor was significantly higher than that in the muscle by more than five-fold (P<0.001). Furthermore, the relatively low bone uptake of [Al18F]NODA-MPAA-HTA suggested that defluorination did not occur in vivo. These preliminary results provide experimental evidence for further study of Al18F-labeled somatostatin analogues as tumor probes for PET imaging of NETs. Conclusion: Fluorine-18 is widely used as a radionuclide for the production of radiopharmaceuticals for positron emission tomography (PET). Due to its short half-life (T1/2,109.8 min), its ease of production will facilitate the widespread dissemination of this radiopharmaceutical. A high-quality [Al18F]NODA-MPAA-HTA was synthesized with satisfactory yield. This radiopharmaceutical demonstrated higher tumor uptake and better tumor-to-muscle contrast, resulting to excellent image quality. These findings suggest that the novel 18F-labeled somatostatin analogue, [Al18F]NODA-MPAA-HTA, is a promising tool for PET imaging of NETs.

Positron Emission Tomography with 18F Labeled Vitamin D Analogs: Can It Locate and Quantify the Vitamin D Receptor in Tumors or Other Tissues

Noninvasive imaging of FAP expression using positron emission tomography: A comparative evaluation of a [18F]-labeled glycopeptide-containing FAPI with [18F]FAPI-42

Evaluation of Tumor Vascular Targeting Agents Labelled with 131I in Imaging of Tumor

Synthesis and Evaluation of Novel F-18 Labeled Fluoroarylvaline Derivatives: Potential Pet Imaging Agents for Tumor Detection

Positron Emission Tomography Imaging of Vascular Endothelial Growth Factor Receptor Expression with 61Cu-Labeled Lysine-Tagged VEGF121

Development of a Novel <SUP>18</SUP>F-Labeled Probe for PET Imaging of Estrogen Receptor

Peptoid And Positron Emission Tomography: An Appealing Combination

Imaging proliferation in vivo with [F-18]FLT and positron emission tomography

Preclinical Evaluation of a Fluorine-18 Labeled Probe for the Detection of the Expression of PSMA Level in Cancer

Development of a Novel F-18-Labeled Probe for PET Imaging of Estrogen Receptor beta

18F Labeled benzimidazole derivatives as potential radiotracer for positron emission tomography (PET) tumor imaging

18F-labeled somatostatin analogs for somatostatin receptors (SSTRs) targeted PET imaging of neuroendocrine tumors (NETs)

Synthesis and Biological Evaluation of (68) Ga-labeled Pteroyl-Lys Conjugates for Folate Receptor-Targeted Tumor Imaging.

Simultaneous Fluorescence and Positron Emission Tomography for in Vivo Imaging of Small Animals

PET Probes Beyond (18)F-FDG.

Development of a Novel 18 F-Labeled Probe for PET Imaging of Estrogen Receptor β.

Design, synthesis and evaluation of novel prostate-specific membrane antigen-targeted aryl [ 18 F]fluorosulfate PET tracers

Research progress of 18F labeled small molecule positron emission tomography (PET) imaging agents

In Vivo Ester Hydrolysis As a New Approach in Development of Positron Emission Tomography Tracers for Imaging Hypoxia.

Preclinic Al Ev Alu Ation of a Novel TSPO PET Lig and 2-(7-butyl-2-(4-(2-[18f]fluoroethoxy)phenyl)-5-methylpyr Azolo[1,5- A]pyrimidin-3-yl)- N, N-Diethyl Acet Amide (18F-VUIIS1018A) to Im Age Gliom A

In Vivo Characterization of Two 18F-Labeled PDE10A PET Radioligands in Nonhuman Primate Brains.